• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vogelxo (testosterone) gel

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vogelxo (testosterone) gel

  • Profile

Profile

Contact Information

Contact: Upsher-Smith
Website: https://www.upsher-smith.com/

Currently Enrolling Trials

    Show More

    General Information

    Vogelxo is a topical gel formulation of testosterone. Endogenous androgens, including testosterone, are responsible for the normal growth and development of the primary and secondary male sexual characteristics.

    Vogelxo is specifically indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).

     

    Mechanism of Action

    Vogelxo is a topical gel formulation of testosterone. Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening and alterations in body musculature and fat distribution.

    Side Effects

    Adverse effects associated with the use of Vogelxo may include, but are not limited to, the following:

    • Application site reactions
    • Increased hematocrit

    Dosing/Administration

    Vogelxo is supplied as a gel for topical administration. The recommended starting dose for adult males is 50 mg of testosterone (one tube or one packet or four pump actuations) applied topically once daily at approximately the same time each day. It should be applied to clean, dry, intact skin of the shoulders and/or upper arms. Do not apply Vogelxo to the genitals or abdomen. If morning predose serum testosterone concentration is below the normal range, increase dose to 100 mg. Predose serum testosterone concentration should be assessed periodically. Patients should wash hands with soap and water immediately after applying Vogelxo and cover application site(s) with clothing after gel has dried.

    Clinical Trial Results

    FDA Approval

    The FDA approval was based on a randomized multicenter, multi-dose, active and placebo controlled 90-day study in 406 adult males with morning testosterone levels ≤300 ng/dL. The study was double-blind for the doses of testosterone gel and placebo, but open label for the non­scrotal testosterone transdermal system. During the first 60 days, subjects were evenly randomized to testosterone gel 50 mg, testosterone gel 100 mg, placebo gel or testosterone transdermal system. At Day 60, subjects receiving testosterone gel were maintained at the same dose or were titrated up or down within their treatment group based on 24-hour averaged serum testosterone concentration levels obtained on Day 30. Of 192 hypogonadal men who were appropriately titrated with testosterone gel and who had sufficient data for analysis, 74 percent achieved an average serum testosterone level within the normal range (300 to 1,000 ng/dL) on treatment Day 90. 

     

     

    Approval Date: 2014-06-01
    Company Name: Upsher-Smith
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing